If you've come across “Wegovy HD” while researching weight-loss options, here's the plain-English answer: it's a real, FDA-approved higher-dose version of the prescription drug Wegovy (semaglutide), approved in March 2026. It's not something you evaluate the way you'd evaluate an over-the-counter supplement, and it's not a drug most people start on directly. This guide walks through what's actually been verified, what the evidence can and can't tell you, and the questions worth bringing to a clinician before you go further.
What Wegovy HD actually is
Wegovy HD is a 7.2 mg weekly injection of semaglutide — triple the previously approved maximum dose of 2.4 mg. The FDA approved it in March 2026 under its Commissioner's National Priority Voucher program, an accelerated review pathway, with the review completed in 54 days. It's indicated for chronic weight management in adults with obesity, or adults who are overweight with at least one weight-related condition.
One detail that's easy to miss in headlines: the FDA label doesn't position this as a starting dose. It's defined for adults who have already been on standard Wegovy (2.4 mg) for at least four weeks and tolerated it, where a clinician determines additional weight loss is appropriate. In practice, this is a step-up option within an existing treatment plan, not a new entry point.
What the clinical trials found
The approval rests on two 72-week studies: STEP UP, which enrolled about 1,400 adults with obesity and no diabetes, and STEP UP T2D, which enrolled roughly 500 adults with obesity and type 2 diabetes. Both compared the 7.2 mg dose against the standard 2.4 mg dose and a placebo, alongside diet and exercise changes.
The results are reported two different ways, and the difference matters for understanding what's actually been shown:
- If everyone had taken the drug exactly as prescribed (what researchers call the efficacy estimand), the STEP UP trial found an average weight loss of about 20.7% on the 7.2 mg dose, versus about 17.5% on the 2.4 mg dose and about 2.4% on placebo. About a third of participants lost 25% or more of their body weight.
- Accounting for real-world adherence — people who stopped early, missed doses, or discontinued — the average drops to roughly 18.7% on the higher dose versus about 3.9% on placebo.
- In the STEP UP T2D trial (adults with both obesity and type 2 diabetes), average weight loss was lower — around 13–14% — with blood-sugar improvement similar to the standard dose.
Neither number is “wrong.” They're answering different questions: one describes the drug's effect under ideal conditions, the other describes what tends to happen across a real population. Marketing material tends to lead with the first number; it's worth knowing both exist.
What the evidence doesn't settle
Trial averages describe a study population, not you specifically. They also don't resolve the trade-off that came with the higher dose: side effects were more common at 7.2 mg than at 2.4 mg. Altered skin sensation — described as sensitivity, pain, or burning — was reported in about 22% of people on the higher dose, compared with about 6% on the standard dose, though it generally resolved on its own or with a dose adjustment. Other commonly reported effects included nausea, vomiting, constipation, abdominal pain, fatigue, and headache, generally more frequent at the higher dose.
Wegovy also carries a boxed warning — the FDA's strongest label warning — regarding a potential risk of thyroid C-cell tumors, based on findings in rodent studies. This applies to semaglutide generally, not just the HD dose, and it's a standard part of the prescribing conversation rather than something unique to this approval. It's the kind of detail a “more weight loss” headline can leave out, and it belongs in an honest evidence summary.
None of this tells you whether the higher dose is the right move for your situation. That depends on your health history, how you tolerated the standard dose, and what your prescriber is watching for — not on a population average.
Why this is a different kind of question than an OTC supplement review
If you landed here after reading about over-the-counter weight-management products, it's worth being clear about the difference. An OTC supplement review is about ingredient transparency and whether label claims match the evidence. Wegovy HD isn't evaluated that way — it went through FDA drug review, with defined trial populations, a specific indication, and a prescribing requirement. The research question isn't “does this work as advertised,” it's “does this fit my medical picture, and what needs monitoring.” Those are different kinds of due diligence, and treating them the same shortchanges the reader either way.
Questions worth bringing to a clinician
- Have I actually met the criteria the FDA label describes — tolerating the standard 2.4 mg dose for at least four weeks — or would starting there make more sense first?
- Given my health history, what does the boxed warning and the higher reported rate of side effects mean specifically for me, and what would we monitor for?
- If I don't respond as expected, or side effects are hard to tolerate, what's the plan — dose adjustment, staying on the standard dose, or a different approach?
These aren't the only relevant questions, but they're a reasonable starting point for a conversation that's about your situation rather than a trial average.
The practical next step
At this stage, the useful move isn't choosing a product — it's reading the actual evidence and bringing informed questions to a clinician visit. If you're also tracking current medications and want to prepare for that conversation, this medication-list guide for weight-management visits covers what's worth bringing in. If you're weighing non-prescription options separately, that's a different evidence standard and a different conversation from this one.